Clinicians should pay close attention to haematological toxicity and hepatoxicity and monitor possible clinical symptoms of these adverse events during the use of HER2-targeted ADCs, especially in patients with underlying known hepatic disease or hematopoietic dysfunction. The gene discussed is ERBB2; the disease is liver disorder.